Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAYNIER MOYA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124288980
CMS profile
278302
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,741.44

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,741.44 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Chiesi USA, Inc. $1,741.44 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAYNIER MOYA

NPI 1124288980 · CMS profile ID 278302

Allopathic & Osteopathic Physicians / Internal Medicine

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $1,741.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Chiesi USA, Inc. $870.7201/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050859851 CMS
Chiesi USA, Inc. $870.7201/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051592383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $128.50 2
PY2023 $1,741.44 2
PY2025 $15.30 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,567,242.14 108
PY2024 Recipient $1,161.49 6
PY2024 Principal investigator $5,059,140.87 296
PY2023 Recipient $2,506.25 1
PY2023 Principal investigator $14,127,127.37 743
PY2022 Recipient $24,618.00 1
PY2022 Principal investigator $15,001,316.81 131
PY2021 Principal investigator $6,255,399.36 48
PY2020 Principal investigator $653,923.11 62
PY2019 Principal investigator $748,551.83 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,380.03 12/31/2021 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia No dispute reported 06/30/2026 826468995
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,696.02 12/31/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER, LLC
A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia No dispute reported 06/30/2026 826485519
Principal investigator 1 PFIZER INC. $867,267.70 12/22/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832556561
Principal investigator 1 PFIZER INC. $910.00 12/22/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832633685
Principal investigator 1 PFIZER INC. $6,227.00 12/22/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832634343
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,651.25 12/16/2021 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia No dispute reported 06/30/2026 826501759
Principal investigator 1 GlaxoSmithKline, LLC. $272,239.79 12/15/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 860871223
Principal investigator 1 PFIZER INC. $330,626.40 12/07/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832556383
Principal investigator 1 PFIZER INC. $5,775.00 12/02/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832633695
Principal investigator 1 PFIZER INC. $5,550.00 12/02/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832633705
Principal investigator 1 GlaxoSmithKline, LLC. $4,500.00 11/25/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809492411
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 11/25/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809492417
Principal investigator 1 GlaxoSmithKline, LLC. $1,352.00 11/25/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809495875
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/25/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809515283
Principal investigator 1 GlaxoSmithKline, LLC. $90,152.01 11/25/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809536605
Principal investigator 1 PFIZER INC. $774,870.20 11/23/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832634009
Principal investigator 1 PFIZER INC. $4,880.88 11/23/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832694241
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 11/17/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809492413
Principal investigator 1 GlaxoSmithKline, LLC. $1,763.85 11/17/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809492415
Principal investigator 1 GlaxoSmithKline, LLC. $70,000.00 11/17/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809515239
Principal investigator 1 GlaxoSmithKline, LLC. $20,000.00 11/17/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809536571
Principal investigator 1 PFIZER INC. $402,022.40 11/05/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832634177
Principal investigator 1 PFIZER INC. $16,561.36 11/05/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832879677
Principal investigator 1 PFIZER INC. $24,648.00 10/29/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832835975
Principal investigator 1 PFIZER INC. $43,219.18 10/28/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832785879
Principal investigator 1 PFIZER INC. $298,188.80 10/21/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832634201
Principal investigator 1 PFIZER INC. $21,299.20 10/08/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832633999
Principal investigator 1 GlaxoSmithKline, LLC. $142,073.10 09/29/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809484253
Principal investigator 1 GlaxoSmithKline, LLC. $139,574.29 09/29/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809485111
Principal investigator 1 GlaxoSmithKline, LLC. $275,255.39 09/29/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809506749
Principal investigator 1 PFIZER INC. $12,000.00 09/22/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832634189
Principal investigator 1 PFIZER INC. $30,000.00 09/22/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832768915
Principal investigator 1 PFIZER INC. $27,913.60 08/21/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832692597
Principal investigator 1 PFIZER INC. $57,020.60 08/06/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832900131
Principal investigator 1 GlaxoSmithKline, LLC. $414,954.11 07/29/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809482153
Principal investigator 1 GlaxoSmithKline, LLC. $376,912.28 07/29/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809487697
Principal investigator 1 GlaxoSmithKline, LLC. $186,322.62 07/29/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 809493031
Principal investigator 1 PFIZER INC. $24,986.00 07/21/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832809713
Principal investigator 1 PFIZER INC. $22,536.80 07/09/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832727289
Principal investigator 1 PFIZER INC. $32,162.00 06/23/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832805671
Principal investigator 1 PFIZER INC. $17,591.60 06/05/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832795601
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,712.75 06/01/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER, LLC
A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia No dispute reported 06/30/2026 826459801
Principal investigator 1 PFIZER INC. $7,371.00 05/21/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832848291
Principal investigator 1 PFIZER INC. $23,223.20 05/07/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A 12WEEK PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06882961 TITRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH METFORMIN AND IN NONDIABETIC ADULTS WITH OBESITY No dispute reported 06/30/2026 832849860
Principal investigator 1 AstraZeneca UK Limited $1,140,504.75 03/24/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER, LLC
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 826485327
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,263.55 03/09/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
AKB-6548-CI-0015 No dispute reported 06/30/2026 855419599
Principal investigator 1 PFIZER INC. $825.50 01/12/2021 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832888817
Principal investigator 1 AKEBIA THERAPEUTICS INC $18,115.15 01/08/2021 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 855419571